Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Systematic review of the literature

Lisa L. Liu<sup>1,2,#</sup>, Marcus Skribek<sup>1,2</sup>, Ulrika Harmenberg<sup>1,2</sup>, Marco Gerling<sup>1,3,#</sup>

\*Corresponding authors:

11 Lisa L. Liu Burström, MD, PhD, email: lisa.liu@ki.se

12 Marco Gerling, Dr. med, email: marco.gerling@ki.se

### **Abstract**

1

2

3

4 5

6

7 8

9

10

13 14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects become increasingly visible in clinical practice and impact therapy decisions.

Here, we provide a systematic review of the literature of CRS and related lifethreatening side effects of ICI treatment, such as hemophagocytic lymphohistiocytosis (HLH). We searched Medline, Embase, and the Web of Science Core Collection from inception until October 2021 for reports on CRS, cytokine storm, macrophage activation syndrome, HLH, and related hyperinflammatory disorders in patients with solid cancers receiving ICIs. We found n = 1866 articles, which were assessed for eligibility independently by two examiners. Of those, n = 49 articles reporting on n = 189 individuals were eligible for review. We found that the median time from last infusion to the occurrence of CRS/HLH was approximately nine days, while the onset of symptoms varied from immediately after infusion to one month after treatment. Most patients were treated with either corticosteroids or the anti-interleukin 6 (IL-6) antibody tocilizumab, and although the majority of patients recovered, a few cases were fatal. Concomitant IL-6 and ICI treatment was reported as beneficial for both the antitumoral effect and for limiting side effects. Data from international pharmacovigilance databases underscored that ICI-related CRS and HLH are rare events, but we identified significant differences in reported frequencies, which might suggest substantial underreporting.

The results from this first systematic review of CRS/HLH due to ICI therapy highlight that life-threatening systemic inflammatory complications of ICIs are rare and non-fatal in the majority of patients. Limited data support the use of IL-6 inhibitors in combination with ICIs to augment the antitumoral effect and reduce hyperinflammation.

<sup>&</sup>lt;sup>1</sup>Theme Cancer, Karolinska University Hospital, 17176 Solna, Sweden

<sup>&</sup>lt;sup>2</sup> Department of Oncology-Pathology, Karolinska Institutet, 17176 Solna, Sweden

<sup>&</sup>lt;sup>3</sup>Department of Bioscience and Nutrition, Karolinska Institutet, 14183 Huddinge, Sweden

## Introduction

43 44

45

46

47

48

49

5051

52

53

54

5556

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

Immune checkpoint inhibitors (ICIs) have become important therapeutic options for various tumor types. ICIs are associated with specific toxicities, commonly referred to as immunerelated adverse events (irAEs), which can lead to treatment interruption or discontinuation. International guidelines aid clinicians in the diagnosis and management of relatively common irAEs, such as skin rashes, colitis, thyroiditis, and pneumonitis<sup>1,2</sup>. However, the increasing volume of patients treated with ICIs is starting to reveal less common side effects, including systemic hyperinflammatory syndromes. Nonspecific systemic inflammatory reactions to ICIs, such as self-limiting fever or skin rashes during or shortly after infusion<sup>2</sup>, need to be distinguished from severe, persistent, and potentially life-threatening conditions such as cytokine release syndrome (CRS) and hemophagocytic lymphohistiocytosis (HLH)/macrophage-activation syndrome (MAS)<sup>3</sup>. Due to their severity, these irAEs are of particular clinical importance and require a decision on continuation of ICI treatment, for which evidence is lacking. Because of their rarity, hyperinflammatory syndrome are incompletely captured in randomized clinical trials with ICIs 4,5, and not yet discussed in irAE guidelines<sup>1,2</sup>. Hence, real-world data and case reports of rare irAEs are needed to understand their frequency and severity, and to improve clinical management.

In cancer therapy, CRS is best understood in the context of chimeric antigen receptor (CAR) T cell therapies, where it occurs in a substantial proportion of patients at different levels of severity<sup>6</sup>. CRS is believed to be mainly driven by T cell-derived interferon gamma (IFN- $\gamma$ ), which stimulates macrophages to produce various pro-inflammatory substances including interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF- $\alpha$ )<sup>7</sup>. Therapeutically, IL-6 inhibition with specific anti-IL-6 receptor antibodies, such as tocilizumab, has proven highly effective against CRS, reflected by the US Federal Drug Agency's approval of tocilizumab for CAR T cell-induced CRS<sup>8</sup>. This is important because IL-6 inhibition could allow for the continuation of any treatment associated with mild CRS<sup>9</sup>.

HLH is an umbrella term for life-threatening hyperinflammatory conditions with supramaximal activation of the immune system. For the diagnosis of HLH, the HLH-2004 diagnostic criteria are frequently used, although they were developed for the pediatric population<sup>3</sup>. The criteria include clinical features such as fever and splenomegaly, as well as laboratory findings such as cytopenias, hypertriglyceridemia, hyperferritinemia, evidence of hemophagocytosis, and the absence of natural killer (NK) cell activity<sup>3</sup>. More recently, the

HScore, which includes similar criteria to HLH-2004, was developed to estimate the probability for reactive HLH in adults with inflammatory syndromes<sup>10</sup>. Genetic analyses from pediatric patients have revealed a wide variety of predisposing variants that presumably play a role for different immune cell types, suggesting that HLH-related conditions represent a complex disease continuum<sup>11</sup>.

Reports on hyperinflammatory syndromes due to ICI treatment have started to emerge during recent years, and have suggested that these are relatively rare, but potentially life-threatening events<sup>12</sup>. Both HLH and CRS can be fatal by causing hypotension, capillary leak syndrome, and consequently organ dysfunction<sup>7</sup>. Because of the potential risk of increasing the severity of CRS/HLH upon repeated exposure to a particular trigger, suspicion of these hyperinflammatory syndromes in clinical practice most often leads to treatment cessation. Hence, a better understanding of this complex disease spectrum in the context of ICI treatment is needed to guide decision-making on treatment continuation and optimal management.

To set the stage for a more evidence-based approach to CRS, we conducted a systematic review of the literature, in which we identify n = 49 articles on n = 189 patients with hyperinflammatory syndromes due to ICIs. The results reveal that most patients with CRS/HLH recover and that a fatal outcome is rare. In addition, the literature reveals that corticosteroids and IL-6 inhibition may provide effective therapies. Extrapolating from preclinical data, which we review in brief, we posit that rechallenging with ICIs after CRS/HLH has been controlled should be considered at least in patients with mild hyperinflammatory ICI side effects who are expected to benefit from ICI treatment. Recent data suggest that ICIs in combination with IL-6 antagonists may boost the antitumoral effect, while simultaneously protecting from severe irAEs, which makes ICIs in combination with IL-6 inhibition an attractive option for rechallenge that warrants further research.

#### Methods

### Systematic review

We performed a systematic search for published reports on CRS, HLH and related hyperinflammatory diseases in MEDLINE, Embase, and the Web of Science databases as of October 2021. The search strategies were designed in collaboration with the Karolinska


Institute library and are included as **Supplementary Figure 1**. Deduplication was performed as previously described<sup>13</sup>.

Additional manual searches were performed based on the lists of references in the eligible studies, and a reduced set of keywords in the MEDLINE database only, as of June 13<sup>th</sup> 2022. Inclusion criteria for abstract review were assessed independently by two reviewers (LLL and MG) and defined as follows: (1) report on any hyperinflammatory syndrome (CRS, HLH, MAS, or any indication of these or related systemic syndromes) on human patients with solid tumors, (2) reported use of any ICI at any time of the treatment, (3) case series or case reports, i.e. no randomized-controlled trial (RCT), unless explicitly stated that CRS/HLH/MAS or any other hyperinflammatory syndrome was reported, (4) articles in English, Swedish, Chinese or German. LLL and MG agreed on article inclusion by discussing the articles for which the initial decision on inclusion differed. For all eligible articles, the full-text was downloaded by LLL or MG. Data were extracted by either LLL, MS, or MG, and all authors convened to agree on final inclusion. As the majority of the included studies were case reports on rare events, no further criteria for study quality assessment were applied and the risk for bias was not assessed. The systematic review was not preregistered.

### Results

### Systematic review

To chart our current knowledge of hyperinflammatory syndromes, such as CRS and HLH, as rare side effects of treatment with ICIs, we conducted a systematic review of the literature housed in the major medical databases as of October 2021. In addition, we manually updated the list of eligible studies as of 13<sup>th</sup> June 2022. **Supplementary Figure 2** presents the PRISMA reporting chart for the study.



**Supplementary Figure 2:** PRISMA 2020 flow diagram of the study.

We identified a total of n = 49 articles, reporting on n = 189 patients treated in the USA, the UK, Switzerland, Spain, Poland, Lebanon, Japan, Israel, Germany, France, China, Canada, Australia, and Singapore (**Table 1**). Of these studies, n = 45 reports were on n = < 5 individual patients (comprising a total of n = 56 individuals), while n = 4 studies reported case series or data from queries of pharmacovigilance databases (**Table 1**). Definitions of CRS/HLH varied significantly between reports, and retrospective diagnostic assessment was not possible due to partially incomplete and heterogeneous clinical data. Therefore, we used the respective authors' assessment of the hyperinflammatory condition as CRS, HLH, or related hyperinflammatory diseases for further analysis. The earliest published report was from  $2016^{12}$ .

The ICIs used included pembrolizumab (n = 21 studies) and nivolumab (n = 11 studies) as single agents, combined treatment with ipilimumab and nivolumab (n = 13), and, less frequently (n = 2 studies each), ipilimumab, sintilimab or atezolizumab monotherapy, and cemiplimab (n = 1). Often, ICIs were combined either with chemotherapeutical agents or other anticancer drugs, such as TKIs (i.e. cabozantinib or dabrafenib/trametinib), or drugs that were used prior to development of the hyperinflammatory syndrome(s).

In the individual reports, n = 15 patients were diagnosed with CRS, n = 34 with HLH, and n = 6 were described as having related hyperinflammatory conditions such as capillary leak syndrome with high fever, or systemic inflammatory response syndrome (SIRS). The most frequently reported underlying malignancies in individual case reports were malignant melanoma (n = 21 individual reports) and lung cancer (n = 14 individual reports). The average age of the patients in the individual reports was 59 years. In individual reports that reported the patients' sex, n = 35 patients were males, and n = 20 patients were females. The highest frequencies of male patients were also reported in the largest case series from two centers in Singapore<sup>14</sup> (n = 18 males, n = 7 females), and in a World Health Organization (WHO) pharmacovigilance database queried for  $HLH^{15}$  (n = 29 males, n = 9 females) and CRS, respectively (n = 34 males, n = 21 females). Most studies (n = 46 studies out of 49) comprised data on patients with metastatic disease (**Table 1**). Time from ICI infusion to onset of symptoms varied from hours to one month, with a median of n = 9 days. In total, n = 42studies on n = 56 individual patients (75%) reported recovery from ICI-induced irAEs, while n = 5 cases (out of 56, corresponding to 8.9%) were fatal. Of those, n = 3 cases were reported to have HLH, and n = 2 had CRS, as per the authors' assessment. Overall, n = 42 patients from individual reports were reported to have recovered from their hyperinflammatory

complications. Reports from pharmacovigilance data were incomplete for outcome data; a study including n = 25 patients from Singapore reported n = 3 fatal cases (0.12 %).

Treatments for CRS/HLH varied significantly, and included different types of corticosteroids in almost all cases, and tocilizumab in n = 14 cases. Various other drugs were used in some patients, including etoposide in combination with dexamethasone, an established HLH treatment<sup>17,18</sup>, as well as intravenous immunoglobulins, plasmapheresis, mycophenolate mofetil, and tacrolimus. Often, these were combined, at least initially, with antibiotic therapy because of suspected sepsis (**Table 1**).

# 179 Table 1: Studies retrieved in systematic review

Authors 'd  Publication  year  Country	<u>Study title</u>	Type of malignancy	No. of patients with CRS	Age & Sex	Tumor burden (stage)	<u>Antibody used</u>	Additional therapy	Main complication (CRS, HLH, other, as assessed by the authors)	Cycle of ICI treatment prior to CRS/HLH	Time from infusion to symptoms (in days)	<u>Main symptoms</u>	Intervention (steroids, IL-6, other)	CRS/HLH- specific outcome after intervention	Rechallenge ICI	Tumor- specific outcome	Com ments
Sharma et al. <sup>32</sup> 2016 USA	Systemic inflammatory response syndrome (SIRS) with immune c heck point inhibitors.	'Progress ive lung cancer'	12		N/A	N ivo lu ma b		SIRS	Unclear		'One or more of the following - fever, tachypnea, tachypnea, tachya dia, hypotension, organ failure occurring 12 days to weeks after immunotherapy.'	Steroids, tocilbumab	Unclear	Unclear	Unclear	Presented as poster; no detailed description of individual cases in published abstract.
El Rassy et al. <sup>19</sup> 2017 Lebanon	Diffuse ede ma suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab	Lung squamous cell carcinoma	1	62 M	Metastatic (stage IV)	Pe mbro lž uma b		CRS	7	1	'Fatigue, persistent low-grade fever and an acute onset of diffuse swelling involving [] limbs and abdomen. [] pain sensation on exertion in both hands and legs."	Furose mide for edema, then steroids.	Recovery	Yes, up to at least 13 cycles.	Unclear	
Shah et al. <sup>20</sup> 2017 USA	Pembro lizuma b associa ted hemo phagocytic lym pho hist iocyt os is	Bladder	1	76 M	Metastatic	Pembro lž uma b		нцн	9 months of therapy	Unclear	Fatigue, fever. Sinus tachycardia, pallor, macub papular rash, and sple no megaly. Pancytopen is. Acute renal failure. Hyperferritinemia and hyperfibrino genemia. Increased soluble IL-2R.	Etopo side, stero ids	Unclear	Unclear	CR	
Rotz et a L <sup>21</sup> 2017 USA	Severe cyto kine release syndro me in a patient receiving PD-1-d irected the rapy	S a r co ma	1	29 F	Metastatic	N ivo lu ma b	Pazo panib	CRS	2	4	Fatigue, myalgias, fever, diffuse macub papub rash, encephab pathy. Fever, tachycardia, hypotension, desaturation and disorientation. Thrombocytopenia, lactic acidosis, acute kidney and liver injury. Abnormal coagulat on studies. Elevated levels of IL-6, IL-8, IL-10, IFN-Y.	IV fluids, steroids, broad- spectrum ABs, tocilizumab.	Recovery	No	Unc lear	
Urosevic- Ma iwa id et al. <sup>22</sup> 2017 Switzerland	Systemic in flammatory reaction syndrome during combined kinase inhibitor therapy following anti- PD-1 therapy for me lanoma	Malignant melano ma	2 (1)	45 F	Metastatic (stage IV)	Pe mbro lž uma b	Dabrafenib/trametinib after IcI progress. Side effects, switched instead to vemurafenib/ cobimet in ib	SIRS		28	Fever, chilb, fatigue. Hypotens ion (38/26 mm Hg), tachycardia, anuria.	Broad- spectrum ABs, steroids	Recovery	No, but rechallenge with ve murafenib/c obimetinib did not result in recurrence		

Cont. Urosevic- Maiwaldet al.		Malignant melano ma	2 (2)	48 F	Metastatic (stage IV)	Pe mbro liz uma b	Vemurafen ib and cobimet in ib after ICI progress	'hypersensitivity syndrome' or DRESS	Unclear	8	Face swelling (including eyes and lips) and a diffuse prufit eruption, composed of erythematous and violaceous macules and papules.  Hypotension, tachycardia and fever > 39°C.	Steroids	Recovery	No	Unclear, but PD after around 7 months	
Takeshita et al. <sup>23</sup> 2017 Japan	Coincidence of immunotherapy- associated hemophagocytic syndrome and rapid tumor regression	Squamous non-small cell lung cancer	1	63 F	Metastatic (stage Iv)	N ivo lu ma b		C RS	2	25	Severe general fat gue and high- grade fever	Methylpredniso lone (1000 mg/day, 3 days, then prednisolone.	Recovery	No	Regression	
Michot et al. <sup>24</sup> 2018 France	Fever reaction and haemophagocyti c syndro me ind uced by im mune c heckpoint in hibitors	Melano ma	1	52 F	Metastatic (stage IV)	Ipilimu ma b	Previously 8 cycles of pembro lizumab, then cerebral stereotactic radiotherapy for a brain metastasis, then ipilimumab.	нін	1 (8 pe mbro lž u- mab)	Initial symptoms unclear, fulminant disease 8 weeks after the last dose of ipilimumab	Initially grade 3 hepatitis, "fever with pancytopenia and disseminated intravascular coagulation 8 weeks after the last ipilimumab cycle."	Steroids, etoposide	Death from brain hemorrhage at metastatic site.	No	Unclear	
Sadaat et al. <sup>25</sup> 2018 USA	He mo phagocytic lym pho hist locyt osis with im mu not he ra py: brief re vie w a nd case report	Malignant melano ma	1	58 M	Metastatic	Pe mbro lž uma b		нін	6	31	Fever, upper normal seed spleen, anemia, thrombocytopen a, hypertriglyceridemia, hyperferit inemia, reduced NK cell activity and elevated sCD163 levels. Na usea, arthralgia. Elevated LDH.	S te ro ids	Recovery	No	CR for 1 year, then relapse.	
Hantelet al. <sup>25</sup> 2018 USA	Severe hemo phagocytic lym pho hist locyt osis in a melano ma patient treated with ipilimumab + nivo lumab	Malignant melano ma	1	35 F	Metastatic	Ipilimu ma b/n ivo l u ma b		нін	"Received first doses"	21	Pallor, Jaundice, tachycardia. Spleno megaly. Hypotension. Anemia, thrombocytopena, elevated bilfrubin. Elevated LOH and CRP. Low haptoglobin. Hyperter/finema, hypertrglyceride mia. Low TSH. Hemophagocytosis and elevated CDS.	IV fluids, steroids.	Recovery	No	CR	Previously progressed on adjuvant ipilimu mab.
Satzger et al. <sup>27</sup> 2018 Germany	Treat ment- related hemophagocytic lymphohstiocyt osis secondary to checkpoint inhibition with nivolumab plus ipilimumab	Malignant melano ma	1	26 F	Metastatic	lpilimu ma b/n ivo l u ma b		НГН	4	7	Increased liver function tests, fever. Elevated IL-2R, bilirubin, hyperferitinemia, hy pofibrino genemia.	Stero ids, myco pheno late mofetil.	Reco very	No	CR	
Shah et al. <sup>28</sup> 2018 USA	A Case of Epstein-Barr Usus-Related He mophagocytic Lymphohisticcyt osis in Association With Pembrolizumab The rapy	Metastatic bladder cancer and thymo ma	1	75 M	Metastatic	Pe mbro lž uma b		HLH	Unclear	Unclear	Fever, fat gue, and acute onset pancytopenia. Elevated ferritin, low fibrinogen, spleno megaly, elevated soluble CD25, and decreased natural killer cell activity. Hemophagocytos is.	Unclear	Unclear	Unclear	Unclear	Active EBV infection at the same time.

Sasaki et al. <sup>29</sup> 2018 Japan	He mo phagocytic lym pho histiocyt osis associated with da brafe nib and tra metinib com bination therapy fo llo wing pembro lizuma bad ministration for advanced me la no ma	Malignant melano ma	1	60 F	Metastatic (stage IV)	Pembro lž umab	Dabrafe nib/tra metinib after ICI progress	HTH	'1 month after last ICI'	13	Fever, hepatos plen or megally, and e pthema mult forme-like targetoid les ions all over the body. Pancytopenia, hyperferri (ine mia, increased liver enzyme leveb, and coagulation abnormalities.	Steroids	Recovery	No, but rechallenged with TKI, no HLH.	PR	Sequential T KI and ICI
Laderian and Koehn <sup>so</sup> 2019 USA	Association of He mophagocytic Lymphohistiocyt osis and Programmed Death 1 Checkpoint Inhibitors	T hymic carcino ma	1	49 M	Metastatic (stage IV)	Pe mbro lž uma b	'Multiagent chemotherapy' prior to ICI treatment.	HLH	Several over the course of one year, unspecified.	Unclear	Gradually worsening pancytopenia, hemophagocytosis on bone marrow exam, no signs of viral infection as a cause for HLH.	Unclear	Deceased	Unclear	'Clinical be ne fit '	
Kog ure et al. <sup>33</sup> 2019 Japan	Cyto kine Re lease Synd rome with Pse udo progressi on in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembro lizumab	Lung ade nocarcino ma	1	67 M	Locally advanced (IIB)	Pembro iz umab		CRS	1	2	Fever, tachycardia, hypotension.	Stero ids	Recovery	Yes	Pseudopro gression, after a cycles of pembrolizu mab PR, continuous treatment with pembrolizu mab, unclear how may cycles> near CR.	
Oda et al. <sup>32</sup> 2019 Japan	First Case of Cyto kine Release Syndrome after Nivo lumab for Gastric Cancer	Gastric adenocarcino ma	1	43 M	Metastatic	Nivo lu ma b		CRS	1	8	'Fever (39.0°C), tac hycardia, appetite loss, malaise.'	Prednisolone, then methylpredniso lone, then mycophenolate mofetil.	Death 'from gastric cancer.'	No	PD	
Noseda et al."5 2019 France, Japan, Germany, Switterland, Canada, USA	Hae mop hago cyt i lym pho hist locyt osis in patients trea ted with im mune check po int inhibitors: ana lysis of WHO global database of individual case safety reports	Melanoma, lung cancer, bladder cancer, renal cell carcino ma, Hodgkin's disease, trans kional cell carcinoma, gastric adenocarcinoma, thymo ma, T-ALL.	38	29 M 9 F		Ipilimu mab, n ivolu mab, per mbrolic umab, atezo itz umab, and combinations of the above.	Antineoplastic drugs in 2 cases, antibacterial drugs in 2 cases.									Reports 34 cases of HLH from an international pharmacovigi lance database; of note, the frequency of HLH per treated case varies per 0.03% (USA) to 0.4% [France].
Lorenz et al. <sup>33</sup> 2019 Germany	He mo phagocyt ic lym pho hist locyt osis second a ry to pembro lizuma b treat ment with ins ufficient res ponse to high-dose stero ids	Prostate	1	68 M	Castration- resistant, metastatic (not further specified)	Pe mbro lž uma b	ADT and enzalutamide	нін	Unclear	Unclear	Fever, hepatos pleno megally, pancytopenia, hyperferrit inemia, elevated serum sil- 2 R hypertriglyceridemia, hypofibrinogenemia, elevated liver enzymes. Hemophagocytos is.	Stero ids, daily plas mapheres is , cyc bs por in A etopo side, tacrolimus .	Recovery	No	CR	(riance).

Okawa et al. <sup>34</sup> 2019 Japan	Pembro iz uma bind uced Auto imm une Hemo lytic Anemia and Hemo phagocytic Lym pho histiocyt	Lung squa mous cell carcinoma	1	78 M	Locally advanced (IIIB)	Pe mbro lž uma b		нін	1	10	Anemia, increased total and indirect bilirubin, reticulocytes and LDH. Autoimmune hemolytic anemia. Fatigue, fever.	Steroids, antibiotics.	Recovery	No	CR	
	osis in Non- small Cell Lung Cancer										Jaundice. Leukocytosis. Serum sIL-2R elevation. Increased D-dimer. DIC. Splenomegaly.					
Chin et al. <sup>35</sup> 2019 Australia	Secondary haemo phago cyti c lym pho histiocyt osis due to c heckpoint inhibitor t he rapy	Malignant melano ma	1	69 F	Metastatic	Nivolumab (maintenance)	Ipilimu ma b/n Ivo lu mab	HLH	Unclear	30	Fevers, lethargy, abdo minal distention, swelling, Hepatospleno megaly Anemia, thrombocytopen ia, hyponatremia, hyporfierritinemia, hypofibrinogene mia and hypertreglyceride mia. CD25 elevation. Reduced NK cell activity.	Steroids	Recovery	No	SD	
Honjo et al. <sup>25</sup> 2019 Japan	Severe cytokine release syndrome resulting in purpura fulmina ns despite successful response to nivolumab therapy in a patient with pleo morphic careinoma of the lung: a case report	Pulmo na ry ple o morphic ca r cino ma	1	52 F	Locally advanced (III)	Nivolumab	Carboplatin + nab- pacitaxe I (consolidation?)	CRS	'After the last nivo lumab ad ministrati on.'	14	Asthenia, fever. Livedo reticub ris with systemic purpura. Thrombocyto penia, increased serum soluble IL-2 receptor, ferritin, triglycerides, LDH, CK, Myocardits (increased CK-MB). Gangrene of lower extremit ies, amputated.	Steroids, thrombomoduli n and my- cophenolate mofetil, hemodiafiltrati on:	Recovery	No	PR	Paraneo plasti c syndrome prior to ICI initiation.
Adashe k and Feld man <sup>27</sup> 2019 USA	Cyto kine Release Syndrome Resulting From Anti- Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists	Lung a de noca rcino ma	1	72 M	Metastatic	Pe mbro lz uma b	Radio therapy, carbo platin, pe metrexed	CRS	3 then again after 4	1	Fever, chills, and hypotension, mental status change the first time. Then hypotension, lactic acidosis, and respiratory distress.	Toc iliz umab	Recovery	Unclear	Unclear	
Siota et al. <sup>88</sup> 2019 USA	Cyto kine Release Syndrome As a Rare Complication of Nivoluma b: A Case Report	Malignant melano ma	1	71 M	Metastatic (stage IV)	N ivo lu ma b		C RS	17	Unclear	Altered mental status, hypotension, tachycardia, fever, hypoxia. Grade 3 macu b papular rash.	Broad- s pect rum ABs, ste roids, to cilz u ma b	Recovery, then relapse 6 weeks later (deceased)	No	PR	
Ta ka hashi et al. <sup>39</sup> 2020 Japan	A case of pembro liz uma bind used hemo phagocytic lym pho hist locyt osis successfully treated with pulse glucocontoid therapy	Lung a de no carcino ma	1	78 M	Metastatic (stage IV)	Pe mbro lž uma b	initially 2 cycles of carbo platin and pemetrexed, then switch because of bacterial pleuritis.	нцн	1	7	High grade fever, liver dysfunction and diarrhea, hy pertriglycer dem is / hy pofibrinogene mia, e le vated ferralin, he mophagocytosis in bone marro w, cyto penia and e levated IL-2R.	Predniso lo ne, antibiotics; laters witch to i.v. methylpredniso lone.	Recovery	No	S D for 3 months	

Ohira et al. <sup>40</sup> 2020 Japan	A case report of fulmina nt cytokine release syndrome complicated by dermato myosit is after the combination the rapy with im mune checkpoint	Renal cell carcino ma	1	78 M	Metastatic (stage IV)	Nivo luma band ipilim uma b		CRS	2	2	'Dermatomyos it is [] high fever, hypotens ion, respiratory failure, impaired consciousness, renal failure, and coagulat on abnormality.'	Stero ids, mycopheno late mofet il, plasma exchange; also in need of intubation and d'alysis.	Recovery	No	S D for 2 months	
Normand et al. <sup>41</sup> 2020 Switzerland	inhibitors  Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1 positive, non- small-cell lung cancer	Lung ade no carcino ma	1	79 M	Metastatic (stage IV)	Pembroli: umab	Carbo platin, pemetrexed, denos umab; whole brain radiation.	CRS	1	1	High fever, renal impairment (lab results), elevated high-sen stitulty tropon in T. confusion, d ys pnoea.	Antibiotics, steroids.	Recovery	No	SD for 6 months	Acute onset, which is ra rely reported.
<b>Gao et al.</b> <sup>42</sup> 2020 China	cancer An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case re port	Esophageal squamous cell carcinoma	1	69 M	Locally advanced	S int ilima b	Docetaxel, neda platin, radiation.	CRS	3	Unclear; symptoms after 6 fractions of radiothera py (2 Gy per fraction).	'Fever, diarrhea, he matological inflammation, renal da mage and so on.'	Methylpredniso lone, tocilizumab, mycophenolate mofetil levothyroxine, and human immunoglo bulin.	Recovery	Unclear	Unclear	
Özdemiret al. <sup>83</sup> 2 02 0 Switzerland	Cyto kine- directed therapy with to cilizumab for im mune checkpoint inhibitor-related hemophagocytic lympho histocyt os s	Malignant melano ma	3 (1)	42 M	Metastatic (stage IV)	lpilimu ma b/n ivo l u ma b		HLH	2	Unclear	Fever, nausea, extreme fatigue and drowsiness. Pancytopenia, he patitis G3, disorder of coagulation- fibrinolysis system, AKIN III.	Systemic steroids, tocilizumab, plasma, low dose heparin prophylaxis.	Recovery	Unclear	CR	Good cytokine overview with suggestions for potential therapies.
Cont. Özdemiret al.		Malignant melano ma	3 (2)	36 M	Metastatic (stage IV)	N ivo lu ma b		нін	5	Unclear	Splenomegaly. Deterioration of general condition, fever and extreme fatigue. Pancytopenia, hepatits G3, disorder of coagulation- fibrinolys system.	Tocilizu mab, stero ids, low dose heparin prophylax is.	Recovery	Unclear	PR	
Cont. Özdemiret al.		Malignant melano ma	3 (3)	3 2 M	Metastatic (stage IV)	lpilimu ma b/n ivo l u ma b		нін	3	Unclear	He patos pleno megaly Deterioration of general condition, fever and extreme fatigue. Pancytopenia, he patils G3, disorder of coagulation- fibrinolys's system.	Tocilizumab, plasma, low dose heparin prophylaxis	Recovery	Unclear	PR	
Azarietal. <sup>64</sup> 2020 UK	First case of hemo phagocytic lympho histio- cytosis secondary to ca boza ratinib with checkpo int inhibitors	Renal cell carcino ma	1	5 4	Metastatic	Nivo luma band ipilim uma b	Cabozantinib	нін	1	6	"Mya gia, fevers, frontal headache, photophobia, blurry vision, and vomiting", later rash, oral ulceration, conjunctivitis and fever, accompanied by kidney failure and elevated liver enzymes, coagulopathy,	Initially Septrin and acyclovir for suspected meningitis, upon deterioration. Meropenem, followed by methylpred niso lone and anakinra.	Recovery	No	Unclear	

											ence phalitis.					
Dupré et a l. <sup>65</sup> 2020 France	Ha e mo phago- cytic lympho hist io- cytosis associated with im mune checkpo int inhibit ors: a descript ive case study and literat ure review	Pulmonary sarcomatoid carcinoma	5 (1)	5 4 M	Metastatic	Pe mbro l≹ uma b		HLH	1	7	Fever, asthenia, dyspnea, bone pain. Bicytopenia (thrombocytopenia, a nemia), hyperferritinemia. Hemophagocytosis.	Steroids, broad- spectrum Abs.	Recovery	Yes	PD	Report of 5 cases from a pharmacovigi lance s tudy.
Cont. Dupré et al.		Malignant melano ma	5 (2)	35 F	Metastatic	Ipilimuma b/n ivo l uma b		HLH	1	2 1	Asthenia, s ple no megaly, thro mbo cyto pe nia. Hemo phago cytos is. Hyperferrit inemia, hy po fibrino gene mia, hy pertriglyceride mia.	Steroids, etoposide, IV immunoglobuli ns, tocilizumab.	Recovery	Yes	SD	
Cont. Dupré et al.		Malignant melano ma	5 (3)	52 F	Metastatic	Ipilimu ma b/pe m bro lizu ma b		нін	'After ipilimumab perfusion.'	30	Asthenia, fever. Hepatic cytolysis. Pancytopenia, hypofibrinogenemia, hyperferritinemia, hypertrglyceridemia. Hemophagocy tosis. Cerebral hemorrhage.	Steroids, etoposide	Deceased	No	PD	
Cont. Dupré et al.		Malignant melano ma	5 (4)	69 M	Metastatic	Ipilimu ma b/n ivo l u ma b		нін	'Five weeks and two cycles after the introduction of the combination.'	U nclear	Fever. Spleno megaly. Cytopenä, hyperferritinemä. Hepatic cytolysis, lymphocytis meningitis.	S te ro ids	Recovery	Yes	PD	Several different combinations of ICIs and TKIs. Low HScore with other ITAEs, diagnosed as HLH. No he mophagoc ytosis.
Cont. Dupré et al.		Me lano ma	5 (5)	27 M	StageIII	Ipilimuma b/n ivo l uma b		HLH	Unclear	Unclear	Fever, anemia, hyperferritinemia. Hemophagocytosis. Hypophysits, lymphocytic meningits, colitis, hepatic cytolysis.	S te ro ids	Recovery	No	Unclear	Received adjuvant pembrolizum ab, progressed, then ipilimumab/p e mbrolizuma b.
<b>A ka g i e t</b> a l. <sup>46</sup> 2020 Ja pa n	He mo phagocytic Lym pho histiocyt osis in a Patient with R he umatoid Arthritis on Pembrolizumab for Lung Adenocarcino ma	Lung ade noca rcino ma	1	74 M	Locally advanced (stage IIIB)	Pe mbro lž uma b		HLH	1	27	Joint swelling, hy pertension, fever 38.9°C, diffuse macular rash. Leu ko penia, a nemia, thro mbocyto penia. High ferrifin level. High D-d imer. He patospleno megaly	Steroids, recombinant thrombomod uli n, G-CSF, etoposide.	Rec o very	No	CR	Active rheumatoid arthritis.
Thummalap alli et al. <sup>®</sup> 2020 USA	He mo phagocytic Lym pho hist locyt osis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glio blastoma	G lio blastoma	1	74 M	Unclear	N ivo lu ma b	Anti-IDO1 inhibitor	HLH	2	17	Elevated ASAT, ALAT, ALP, total bilirubin. Fever, altered mental status, leuko penia, neutropenia. Spleno megaly. Hype rierritinemia, IL- 6. Hypertriglyceridemia.	Steroids, vancomycin, ceftazidime, met ronidazole, amphote ricin B, a cyclovir, and atovaquone.	Deceased	No	Unclear	

Mizuta et al. <sup>48</sup> 2020 Japan	He mo phagocytic lym pho hist locyt osis with advanced mailig nant me la no ma accompanied by ipilim uma band nivo lumab: A	Malignant melano ma	1	69 F	Metastatic	Ipilimu mab/nivo l u mab		HLH	2	1	Fever, malaise, headache, grade 2 diarrhea, thirs t, elevated liver en zymes, elevated CRP and LDH. Thrombocytopenia, D-dimer elevation. Lymphadenopathy.	NSAID, levofloxac in, stero ids	Unclear	Unclear	Unclear	
Ceschiet al.16 2020 WHO database, inc. reports from N. America, Europe, Australia,	case report and literature review Imm une Checkpo int Inhib Ror-Re is ted Cyto kine Re lease Syndrome: Analysis of WHO Gio bail Pharma covigilla n ce Database	Melanoma, lung cancer, other unspecified cancers	58 cases, 42 patients with non- he matol ogical maligna ncies.	Med. age 55 y (inc. hem atolo gical cases ).	Unckar	Ipilimumab, nivolumab, pembro le umab, cemipilimab, atezo le umab, avelumab and combinations.	Co-sus pected drugs were antine oplastic agents in 18 cases and 5 other unspecified drugs.	CRS	10 cases aftera single ad ministrati on.	"A median of 4 weeks after ICI initiation."	"CRS, defined accordingly to the correspondent MedDRA PT cytokine release syndrome' (MedDRA version 21.1)."	No reported	Two fatal cases, unknown outcome in 20 cases	Unclear	Unclear	
Japan.  Kalmuket al. <sup>49</sup> 2020  USA	Pembro iz uma b- ind uced Hemo phagocytic Lym pho histiocyt osis: an immuno thera pe utic challe nge	O ro pharyngeal squamous cell carcinoma	1	21 F 61 M	Metastatic	Pe mbro lž uma b	Cis plat in, rad b thera py, as pirin / clo pid og re l.	нін	14	4	Fever, malaise, pancytopenia, transaminitis. He patospleno megaly . Hyperferritine mia, hy pofibrinogene mia, hy pertriglyceride mia. Elevated sll-2 R.	Antibiotics , steroids , etoposide	Recovery	Yes	SD for 8 months	
Hu et al. <sup>50</sup> 2020 China	Pulmo nary fibrosis and cytokine release syndro me after hyperactivation with sintilima b	Cobn	1	50 M	Metastatic	S intilima b		Pulmonary fibrosis with cytokine storm.	2	1	Fever, hypotension, dyspnea, desaturation. Type I respiratory failure. Pulmonary ede ma and cardiogenic shock. Elevated D- dimer and BNP. Elevated IL-6 and IL- 10. Elevated CRP.	IV fluids, vasopressors, steroids, broad- spectrum ABs, nintedanib.	Recovery	Unclear	Unclear	Pulmonary fibrosis due to CRS. Previously received Nivolumab without irAE.
Nieves- Borre ro et al, <sup>51</sup> 2 02 0 USA	Atezolizu mab associated with tumor lysis syndro me, cytokine release syndro me, a nd autoimmune toxicity	Small cell lung cancer	1	68 M	Metastatic	Atezo lizu ma b	Carbo platin, etopos ide	C RS	1	3	Acute kidney injury, elevated lactate, phosphorus, potassium uric acid and LDH. Hypotension, cardiac arrest. Elevated IL-6, CRP, IB-N y and ferritin. Elevated ASAT/ALAT and bilirubin.	He mo dialy sis, renal replacement the rapy.	Deceased	No	Unclear	
Dudda et al. <sup>52</sup> 2 02 0 Germany	He mo phagocytic lym pho histiocyt osis of a me la no ma patient under BRAF/MEK inhibitor thera py following anti- PDI inhibitor treat ment: a case report and review to the literature	Malignant melano ma	1	Uncl ear Uncl ear	Metastatic (stage IV)	Nivo lu ma b	Dabrafenib/tra metin ib after ICI progress.	HLH	Unclear	21	Elevated CRP, procalciton in, splenomegaly, fever. Pancytopenia. Hyperfer finemia, increased s CDS receptor, hypertrighyceridenia, hypofibrino genemia.	Broad- spectrum Abs.	Recovery	No, but rechallenge with we murafenib and cobimetinib (different BRAF/MEKI).	PR	Sequential TKI and ICI.

Amiani et al. <sup>53</sup> 2020 Canada	Successful Treatment of Cyto kine Re kase Syndrome with IL-6 Blockade in a Patient Transitioning from Immune- Checkpo int to MEK/BRAF Inhibit on: A Case Report and Review of Lite rature	Malignant melano ma	1	58 M	Metastatic (stage IV)	N ivo lu ma b	Dabrafenib/tra metinib after Icl progress. Side effects, switched instead to vemurafen ib/cobimeti nib.	CRS	Unclear	Unclear	Fatigue, malaise, and chills. Severe nausea, vo miting, diarrhea, fever of 39°C, and a purpuric eruption on his bower extremities. Distributive shock not responsive to fluids. Transaminitis, at rial fibrillation. Oliguric acute kidney injury, worsened anemia and thrombocytope na, and confusion. NO hemophagocytos 8. Encepha b pathy. Acute as piration. Elevated IL-6, IL-10, INN, ThFa.	Broad- spectrum ABs, ste roids, to cile uma b	Recovery	No	Unclear	TKI and ICI
Yo mo ta et al. <sup>54</sup> 2 02 1 Japan	Cyto kine Re lease Synd ro me Ind uced by Immune- check point Inhibitor The rapy for Non-small-cell Lung Cancer	Lung a de no carcino ma	1	53 M	Metastatic (stage IV)	Atezo lž u ma b	Cisplatin, pemetrexed, radiation .	CRS	1	7	'High fever, rash, DIC, reduced Evelof consciousness, heart failure with LVEF reduced to 20% from normal at baseline."	Initially methylpredniso lone, tocilizumab from day 11; supportive therapy requiring vasopressors.	Recovery	No	PR	
Percik et al. <sup>55</sup> 2021 Is rael	Ca pillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint- inhibitors t reatment	Malignant melano ma	2 (1)	58 M	Stage IIIB	Nivoluma band ipilim uma b	No	Capillary-leak syndrome.	Nivolumab single	21	Genera lized ede ma	Discontinuation of ICI	Initial recovery, followed by severe proximal muscle weakness and death one month later.	No	PR	
Cont. Perciketal.		Duodenal adenocarcino ma	2 (2)	72 F	Stage II	Pembrolz umab and 'an investigational CTLA-4 blocker.'	Unclear if combined	Capillary-leak syndrome.	FOLFOX initially, then 5 FU, irinotecan and be vacizuma b and radiation at time of relapse.	1	Fever, fatigue, bilatera lleg swelling weight gain.	S te roids	Recovery	Unclear	Unclear	
Del Bello et al. <sup>56</sup> 2 02 1 France	Cytokine storm induced by PD1 inhibitor in a renal transplant patient	SCC	1	81 M	Unclear	Cemiplimab	Tacrolimus, mycophenolic acid, steroids (reduced doses)	Cytokine storm, rejection of renal graft.	i	7	Septic shock (unclear specific symptoms), renalfailure.	S te ro ids	Dialysis, kidney necrosis transplantecto my. complications after surgery leading to death.	No	Unclear	Acute rejection of ren al transplan ts after ICI.
Sac Isate in et al. <sup>67</sup> 2 02 1 USA	Pembroi lz uma bind wed cytokine relasse syndro me in a patient with metastatic lung ade noca relinoma : a case report	Lung a de noca rcino ma	1	55 M	Metastatic	Pembro Iz umab	Pemet rexed, carbopb tin, SRS of brain.	CRS	3	19	Fever, chills, hypotens ion, tachypnea, lethargy. Elevated inflammatory markers (ferritin, erythocyte sedimentation rate and C reactive protein) as well as elevated LDH, serum amino-transferases, acute kidney injury, a boute lymphocytopenia with normal hemoglobin and	Vasopressors, IV fluids, broad- ty fluids, broad- spectrum ABS, sten ids, wermed in, hemod alysis, tocilz u mab	Recovery	Unclear	Unclear	

											platelet count, and moderate neutropenia. Elevated IL-6. Encephalopathy with aphasia and somnolence.					
Olivares- Hernández et al. <sup>55</sup> 2021 Spain	Resporse to Treatment with an Anti- interie ukin-6 Receptor Antibody (Tocilizu mab) in a Patient with He mophagocytic Syndrome Secondary to Imm une Checkpoint Inhibitors	Choroida I me la noma	1	75 F	Metastatic	Ipilim uma b		нцн	3	Unclear	The mbody to penia. Sple no megaly. Hyperfer rit nemia, hypertrighye endema, hyportrightye endema, a nemia. Fever, elwa tion of GRP. Elevated IL-2.	Stero ids, to cilizu ma b.	Recovery	Unclear	PR	Previous ly received nivo lu ma b.
Kurozumi et al. <sup>59</sup> 2021 Japan	Two cases of lung cancer with hemophagocytic lymphohist locyt osis caused by im mune check point inhibitors	Lung ade noca rcino ma	2 (1)	75 M	Metastatic	Pe mbro lž uma b		HLH	1	10	Fever, elevated liver enzymes, cyto penia, coagulo pat hy, hyperferritinemia.	S te ro ids	Unclear	Unclear	Unclear	
Cont. Kurozumi et al. <sup>59</sup>		Lung a de no carcino ma	2 (2)	60 F	Locally advanced (IIIB)	Pe mbro lž uma b	Pemet rexed, chemot hera py (?)	нін	'After last dose of pembro lizu mab.'	30	Cytopenia, coagulation abnormalities, and elevated liver enzyme levels, hyperferritinemia.	Stero ids	Unclear	Unclear	Unclear	
Masood et al. <sup>60</sup> 2021 USA	Secondary hemo phagocytic lym phoh shi toyt osis due to nivo luma b/ipili mu ma b in a renal cell cancer patient — A case re port	Renal carcino ma	1	68 M	Metastatic	Ipilmumab∕nivol umab		нін	'Maintenan ce nivo luma b.'	Unclear	Decreased appetite, dizilness, genera lized weakness, and declining performance status. Intermittent fevers with associated tachyacidia. Symptomatic hyponatremia and pancytopenia. Hyperferrikmemia, hyperfiligkyeridemia, bow Nicellactivity, sCD25 elevation. Spieno megaly. NO hemopha gocytosis.	Stero ids	Recovery	Unclear	Unclear	
Pachokzak Madejet al. <sup>52</sup> 2021 Poland	Effect ive Treat ment of a Me is no ma Patient with Hemophago- cytic Lympho hist io- cytosis after Nivo luma b a nd Ipilimumab Combined Immunotherapy	Malignant melano ma	1	57 F	Metastatic	Ipilimu ma b/n ivo I u ma b		нцн	4	Unclear	Fever, general malake, dyspnea at rest and ek vated markers of inflammation and LDH. Elevated CPP and procalettonin. DIC. Hyperfer filine mia, hyp off brinn ogenemia, bw a PTT, high INR. Hypertrig lyceridemia. Splenomegaly.	S tero ids, FFP, mycophenolate mofestil, cyclophos pham ide, eto pos ide, cyclo sporin.	Recovery	No	PR	Radiotherapy after PR.

Tiu et al. <sup>©</sup>	A Wolf in	NSC LC	3 (1)	59	Metastatic	Unclear		HLH	1	11	Fever, rigors,	Broad-	Recovery	Unclear	Unclear	
2021 UK	Sheep's Clothing: Systemic Immune Activation Post Immunotherapy			F							lymphopenia, thrombocytopenia, elevated LDH, elevated transaminases, hypertriglyceridemia, hyperferritinemia, hemophagocytosis.	s pectrum ABs, stero ids, PPIs.				
Cont. Tiu et al. <sup>©</sup>		Breast cancer	3 (2)	42 F	Metastatic	Unclear		нін	1	11	Fever, macub papular rash, thrombocytopena, elevated LDH, transa minitis, hypertriglyceride mia. Normal ferrllin, then hyperferritinemia 3 days after first fever episode. Dyspnea, hypoxia.	Broad- spectrum ABs, steroids, PPIs, tocilizumab.	Reco very	Unclear	Unclear	
Cont. Tiu et a1.€		Bladder can cer	3 (3)	67 M	Metastatic	Unclear		нцн	1	10	Fever, rigors , thrombocytopen ia, lymphopenia, hyperferritinemia . Respiratory failure (type 2). Hemophagocytosis. Elevated IL-1, IL-6, IL-8, IL-10, IFNY, TNFox.	Broad- spectrum ABs, stero ids, tocilizu ma b, siltuxima b, ana kinra, hemo filtration, therape utic plas ma exchange, IV immuno glo buli ns.	Recovery	Unclear	Unclear	
Ta yet al. <sup>14</sup> 2022 Singapore	Cyto kine Release Syndro me in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature	NSC LC, renal cell care ino ma, hepatoce lilular care ino ma, mela no ma.	25	Med. age 64 18 M 7 F	Metastatic (stage IV)	Pembro lizu mab, n Wolumab, ipilimumab, anti- LAG3-antibody.	Concomitant chemotherapy: 6, concomitant radiation: 4, concomitant TKI: 4.	C RS		Median of 11d ays after ICI initiation.	All had fever of 38°C or higher.	Steroids, tocilžumab	3 fatal (of those who received tocilizumab, unclear if more).	In 7 patients, no grade 3/4 events.	PR: 6, SD: 5, PD: 10	Out of n=539 patients receiving ICIs, correspondin g to 4.6% of all ICI treated patients.
Zhang et al. <sup>59</sup> 2022 China	Cytokine release syndrome and successful response to pembro ilsumb therapy in a patient with EGFR-mutated non-small-cell lung caneer: A case report	Lung ade noca rcino ma	1	67 F	Metastatic	Pembro lz uma b		C RS	Unclear	1	Fever, nausea, vomiting, and chest pain. CRP and procalciton in elevation. Hypotension, hypoxemia, tachycardia, and rash. Transaminase elevation, acute kidney injury, and disseminated intravascular coagubtton. T cell and TN Fa elevation.	Broad- spectrum Abs, IV fluids, oxygen, steroids.	Recovery	No	PR	

### **Discussion**

CRS and HLH are potentially life-threatening side effects of treatment with ICIs; however, they are relatively rare and therefore are challenging to study. In this systematic review, we provide a comprehensive picture of the reported cases in the literature to date. Our results underscore the notion that hyperinflammatory syndromes are rare, often treatable, and rarely fatal (**Table 1**).

It is interesting to note the predominance of male patients in both case reports and small case series, as well as in pharmacovigilance databases. This might partly be driven by a higher proportion of men among lung cancer patients<sup>64</sup>, which represent the second largest tumor group in the identified studies, and partly by sex differences in the immune response<sup>65</sup>. Interestingly, pharmacovigilance data suggest that the outcome of CRS is more favorable in females than in males<sup>16</sup>, warranting further research into sex differences in response to treatment and in side effect profiles of ICIs.

Wider indications and lower costs have continuously led to higher numbers of patients being treated with ICIs. Hence, the clinical need to understand rare side effects has increased, and higher patient numbers allow more informed clinical decisions. A common clinical dilemma in patients receiving ICIs is whether to continue treatment despite severe, and potentially life-threatening irAEs. Key factors in this decision-making process are the risk of recurrence of a given irAE, the anticipated severity in case of recurrence, as well as its treatability. A recent study has suggested that IL-6 blockade given in parallel with ICIs ameliorates ir AEs, while enhancing the antitumoral effect of ICIs<sup>66</sup>. Earlier experimental data had already hinted at the potential benefit of adding IL-6 inhibitors to ICIs in mouse models of pancreatic cancer<sup>67</sup> (which is largely resistant to ICI therapy), as well as hepatocellular carcinoma<sup>68</sup>. Together, these data suggest that IL-6 blockade does not abrogate, but rather enhances, the activation of a beneficial antitumoral immune response, providing a potential oncological rationale for combining IL-6 inhibition and ICIs. Results from CAR-T cell therapy in hematological malignancies support the lack of antagonistic effects of IL-6 antagonists in combination with ICIs; for example, in refractory large B-cell lymphoma, response rates to CAR T cell therapy were independent of the use of concomitant tocilizumab to treat CRS<sup>69</sup>.

Our review of the literature revealed that IL-6 inhibitors have successfully been used in cases of hyperinflammatory irAEs upon ICI treatment (**Table 1**). Given the evidence that combined anti-IL-6/ICI treatment enhances the antitumoral effect and is highly effective for

CRS, an important open question is whether a rechallenge after mild CRS/HLH that responded well to anti-IL-6 treatment or corticosteroids should be considered. As shown in **Table 1**, only a few case reports exist on ICI rechallenge after CRS or HLH: One patient with metastatic oropharyngeal squamous cell carcinoma developed HLH after cycle 14 of pembrolizumab and was successfully treated with dexamethasone and etoposide<sup>49</sup>. Eight months after this episode, during which no treatment was given, tumor progression was noted, and the patient was restarted on pembrolizumab without signs of recurrent HLH after five additional cycles<sup>49</sup>. Another patient with a locally advanced lung adenocarcinoma developed CRS after the first cycle of pembrolizumab as first-line treatment, and was successfully treated with methylprednisolone<sup>31</sup>. Pembrolizumab was restarted while the patient was on low dose oral corticosteroids; the patient experienced no relapse of CRS and showed a near-complete tumor response to pembrolizumab<sup>31</sup>.

As a higher tumor burden has been shown to correlate with increased inflammation parameters and cytokine levels<sup>70</sup>, it can be hypothesized that pre-treatment tumor burden is associated with the risk of developing irAEs. Indeed, studies of CAR T cell treatment for B cell acute lymphoblastic leukemia (B-ALL) have shown a significant correlation between severe CRS and a high tumor burden<sup>71,72(p19)</sup>. In the largest case series published containing n = 25 cases, n = 7 were cases after rechallenge with ICIs; none of these had grade 3 or 4 CRS<sup>14</sup>, which lends some support for continuous ICI treatment despite CRS and could be appropriate in selected cases, as the risk of aggravated side effects when re-exposing patients to ICIs could be low.

While we mostly found case reports, two studies reported pharmacovigilance data from the global WHO database, and two reports queried the Registry of Severe Adverse Reactions to Immunomodulatory Antibodies used in Oncology (REISAMIC), a database for ICI-related irAEs in France<sup>24,45</sup>. The first report on REISAMIC data included n = 16 patients with "fever reaction" to ICI treatment, and based on their analysis of these cases, the authors concluded that this irAE can "usually be controlled with a short course of corticosteroids". The second report also queried two other French databases specifically for HLH cases, and identified n = 5 patients with HLH, one of which was fatal. In n = 3 of the five cases, rechallenge of ICI was reported, in n = 2 cases without recurrence of fever of HLH<sup>45</sup>. One of the HLH cases was identified in REISAMIC among n = 745 patients included "at a single center between 2014 and 2019", suggesting that HLH indeed is a rare event. The rarity of HLH is also supported by the analysis of WHO pharmacovigilance data: 49,883 ICI-related adverse events were retrieved from the WHO database VigiBase on a search conducted in

September 2018, n = 38 of whom corresponded to HLH, and n = 34 were directly linked to ICI treatment, usually developing more than six weeks after ICI treatment. Interestingly, the rate of other irAEs was below  $20\%^{15}$ . The same group of authors queried VigiBase for CRS as of January 2020. They found n = 58 reports likely corresponding to CRS among a total of 80,700 reports on ICI-related adverse events, of which n = 43 were definitely related to ICIs, and which occurred a median of approximately four weeks after initiation of ICI treatment<sup>16</sup>. Two of those cases were fatal. Finally, a recent study presented a case series collected at two hospitals in Singapore between February 2014 and January 2021. They found that n = 25 out of a total of n = 539 patients that had received ICI developed CRS, which is a considerably higher frequency than suggested by the pharmacovigilance data, and the reason for this difference is unclear. In this cohort, n = 7 patients with low grade CRS were rechallenged with ICIs and did not relapse. A total of n = 3 cases had fatal CRS despite tocilizumab treatment<sup>14</sup>. The authors also suggested that time-to-fever-onset, low platelet count and high urea levels at CRS presentation might serve as indicators of a severe course<sup>14</sup>.

Although several studies have reported an association between irAEs and improved treatment outcome<sup>73,74</sup>, it is still debatable whether ICI rechallenge after irAEs might be oncologically favorable. In accordance with current guidelines, the majority of patients with grade 3 or 4 irAEs will discontinue treatment with ICI permanently. The rarity of cases, resulting in cohorts of limited size, poses a challenge when addressing the question of ICI rechallenge. While recent studies have shown that rechallenge with ICI after irAE does not significantly improve overall survival<sup>75</sup>, others have concluded that irAEs upon rechallenge display milder toxicities, and suggested that rechallenge might be safe for most patients, depending on the type of irAE<sup>76,77</sup>. Furthermore, a meta-analysis of patients with non-small cell lung cancer rechallenged with ICIs suggests that certain patients with disease progression during ICI discontinuation might benefit from ICI rechallenge<sup>78</sup>. Whether these data are applicable to ICI-related CRS remains to be seen.

In summary, the published data suggest that CRS and HLH are infrequent, potentially severe, but frequently treatable side effects of ICIs, and that rechallenge could be considered in selected cases, with IL-6 inhibition as an attractive preventive and therapeutic option.

## **Declarations**

### Availability of data and material

Data are available from the authors upon request.

### **Competing interests**

The authors declare no competing interests.

# **Funding**

This study received no dedicated funding. MG is supported by The Swedish Research Council (grant number 2018-02023), LLL is supported by The Swedish Society of Medicine and Swedish Society for Medical Research (grant number P17-0134).

## **Authors' contributions**

LLL and MG conceived the study and performed the literature search together with the librarians of Karolinska Institute's library. LLL, MS, and MG decided on study inclusion and collected the data for the systematic review. LLL, MG, and UH collected and interpreted the data from the clinical case. MG wrote the manuscript, LLL, MS, and UH edited the manuscript.

## Acknowledgements

The authors are grateful to Narcisa Hannerz and Sabina Gillsund of the Karolinska Institute's Library, for expert help in conducting the systematic literature search. We are grateful to Marie Meeths for advice on the manuscript.

#### References

- 1. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119–iv142. doi:10.1093/annonc/mdx225
- 2. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update | Journal of Clinical Oncology. [accessed June 15, 2022]. https://ascopubs.org/doi/full/10.1200/JCO.21.01440
- 3. La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–2477. doi:10.1182/blood.2018894618
- 4. Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evidence-Based Medicine. 2018;23(1):6–6. doi:10.1136/ebmed-2017-110885
- 5. Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622320976996. doi:10.1177/2040622320976996
- 6. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e127. doi:10.1016/j.bbmt.2018.12.756
- 7. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96. doi:10.1038/s41577-021-00547-6
- 8. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23(8):943–947. doi:10.1634/theoncologist.2018-0028
- 9. Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705–714. doi:10.2147/TCRM.S223468
- 10. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi:10.1002/art.38690
- 11. Meeths M, Bryceson YT. Genetics and pathophysiology of haemophagocytic lymphohistiocytosis. Acta Paediatrica. 2021;110(11):2903–2911. doi:10.1111/apa.16013
- 12. Sharma N, Stroud CRG, Walker PR, Cherry CR, Cherukuri SD, Addepalli S, Parent T, Hardin J. Systemic inflammatory response syndrome (SIRS) with immune checkpoint inhibitors. JCO. 2016;34(15 suppl):3061–3061. doi:10.1200/JCO.2016.34.15 suppl.3061

- 13. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240–243. doi:10.3163/1536-5050.104.3.014
- 14. Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A, et al. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. Front Immunol. 2022;13:807050. doi:10.3389/fimmu.2022.807050
- 15. Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019;7(1):117. doi:10.1186/s40425-019-0598-9
- 16. Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020;11:557. doi:10.3389/fphar.2020.00557
- 17. Henter J-I, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi:10.1002/pbc.21039
- 18. Henter J-I, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373. doi:10.1182/blood-2002-01-0172
- 19. Rassy EE, Assi T, Rizkallah J, Kattan J. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab. Immunotherapy. 2017;9(4):309–311. doi:10.2217/imt-2016-0134
- 20. Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403. doi:10.1093/annonc/mdx113
- 21. Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer. 2017;64(12). doi:10.1002/pbc.26642
- 22. Urosevic-Maiwald M, Mangana J, Dummer R. Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Annals of Oncology. 2017;28(7):1673–1675. doi:10.1093/annonc/mdx187
- 23. Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Annals of Oncology. 2017;28(1):186–189. doi:10.1093/annonc/mdw537
- 24. Michot J-M, Pruvost R, Mateus C, Champiat S, Voisin A-L, Marabelle A, Lambotte O. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. Ann Oncol. 2018;29(2):518–520. doi:10.1093/annonc/mdx701

- 25. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report PMC. [accessed June 21, 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989389/
- 26. Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018;6(1):73. doi:10.1186/s40425-018-0384-0
- 27. Satzger et al Treatment-related hemophagocytic lymphohistiocytosissecondary to checkpoint inhibition with nivolumab plusipilimumab Google Suche. [accessed June 21, 2022]. https://www.google.com/search?q=Satzger+et+al+Treatment-related+hemophagocytic+lymphohistiocytosissecondary+to+checkpoint+inhibition+with+niv olumab+plusipilimumab&rlz=1C5GCEM\_en&oq=Satzger+et+al%09Treatment-related+hemophagocytic+lymphohistiocytosissecondary+to+checkpoint+inhibition+with+niv olumab+plusipilimumab&aqs=chrome..69i57.317j0j4&sourceid=chrome&ie=UTF-8
- 28. 168 A Case of Epstein-Barr Virus-Related Hemophagocytic Lymphohistiocytosis in Association With Pembrolizumab Therapy ProQuest. [accessed June 21, 2022]. https://www.proquest.com/openview/ccce829a40174af9e581abea320c369b/1?pq-origsite=gscholar&cbl=586299
- 29. Sasaki K, Uehara J, Iinuma S, Doi H, Honma M, Toki Y, Ishida-Yamamoto A. Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma. Ann Oncol. 2018;29(7):1602–1603. doi:10.1093/annonc/mdy175
- 30. Laderian B, Koehn K, Holman C, Lyckholm L, Furqan M. Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors. J Thorac Oncol. 2019;14(4):e77–e78. doi:10.1016/j.jtho.2018.11.035
- 31. Kogure Y, Ishii Y, Oki M. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non–Small Cell Lung Cancer Treated with Pembrolizumab. Journal of Thoracic Oncology. 2019;14(3):e55–e57. doi:10.1016/j.jtho.2018.11.025
- 32. Oda H, Ishihara M, Miyahara Y, Nakamura J, Kozuka Y, Iwasa M, Tsunoda A, Yamashita Y, Saito K, Mizuno T, et al. First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer. Case Rep Oncol. 2019;12(1):147–156. doi:10.1159/000496933
- 33. Lorenz G, Schul L, Bachmann Q, Angermann S, Slotta-Huspenina J, Heemann U, Küchle C, Schmaderer C, Jäger M, Tauber R, et al. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids. Rheumatology (Oxford). 2019;58(6):1106–1109. doi:10.1093/rheumatology/key447
- 34. Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med. 2019;58(5):699–702. doi:10.2169/internalmedicine.1001-18
- 35. Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. Eur J Cancer. 2019;115:84–87. doi:10.1016/j.ejca.2019.04.026

- 36. Honjo O, Kubo T, Sugaya F, Nishizaka T, Kato K, Hirohashi Y, Takahashi H, Torigoe T. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7(1):97. doi:10.1186/s40425-019-0582-4
- 37. Adashek ML, Feldman M. Cytokine Release Syndrome Resulting From Anti-Programmed Death-1 Antibody: Raising Awareness Among Community Oncologists. J Oncol Pract. 2019;15(9):502–504. doi:10.1200/JOP.19.00160
- 38. Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report | Blood | American Society of Hematology. [accessed June 21, 2022]. https://ashpublications.org/blood/article/134/Supplement\_1/5630/425558/Cytokine-Release-Syndrome-As-a-Rare-Complication
- 39. Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y. A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy. Respir Med Case Rep. 2020;30:101097. doi:10.1016/j.rmcr.2020.101097
- 40. Ohira J, Kawamoto M, Sugino Y, Kohara N. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore). 2020;99(15):e19741. doi:10.1097/MD.0000000000019741
- 41. Normand CV, Zender HO, Staehli DM, Chouiter-Djebaili AF, John G. Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer. J Oncol Pharm Pract. 2021;27(6):1528–1533. doi:10.1177/1078155220980813
- 42. An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report Gao Annals of Palliative Medicine. [accessed June 21, 2022]. https://apm.amegroups.com/article/view/47672/html
- 43. Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, de Leval L, Michielin O, Obeid M. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol. 2020;31(12):1775–1778. doi:10.1016/j.annonc.2020.08.2101
- 44. Azari AE, Stratton R, Singh A. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors. Rheumatology. 2021;60(5):e167–e168. doi:10.1093/rheumatology/keaa750
- 45. Dupré A, Michot J-M, Schoeffler A, Frumholtz L, Baroudjian B, Delyon J, Lebbe C, Lambotte O. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. British Journal of Haematology. 2020;189(5):985–992. doi:10.1111/bjh.16630
- 46. Akagi Y, Awano N, Inomata M, Kuse N, Tone M, Yoshimura H, Jo T, Takada K, Kumasaka T, Izumo T. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. Intern Med. 2020;59(8):1075–1080. doi:10.2169/internalmedicine.3889-19

- 47. Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma FullText Case Reports in Oncology 2020, Vol. 13, No. 2 Karger Publishers. [accessed June 21, 2022]. https://www.karger.com/Article/FullText/507281
- 48. Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatologic therapy. 2020. doi:10.1111/dth.13321
- 49. Kalmuk J, Puchalla J, Feng G, Giri A, Kaczmar J. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge. Cancers Head Neck. 2020;5:3. doi:10.1186/s41199-020-0050-3
- 50. Hu J, Li Y, Chen X, Luo C, Zuo X. Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. Journal of Clinical Pharmacy and Therapeutics. 2020;45(6):1474–1477. doi:10.1111/jcpt.13217
- 51. Nieves-Borrero K, Adler S, Pow-anpongkul P, Yeh J. ATEZOLIZUMAB ASSOCIATED WITH TUMOR LYSIS SYNDROME, CYTOKINE RELEASE SYNDROME, AND AUTOIMMUNE TOXICITY. In: AMERICAN JOURNAL OF KIDNEY DISEASES. Vol. 75. WB SAUNDERS CO-ELSEVIER INC 1600 JOHN F KENNEDY BOULEVARD, STE 1800 ...; 2020. pp. 613–613.
- 53. Amlani A, Barber C, Fifi□Mah A, Monzon J. Successful Treatment of Cytokine Release Syndrome with IL□6 Blockade in a Patient Transitioning from Immune□Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature. Oncologist. 2020;25(7):e1120–e1123. doi:10.1634/theoncologist.2020-0194
- 54. Yomota M, Mirokuji K, Sakaguchi M, Kitahara Y, Chin F, Setoguchi K, Hosomi Y. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer. Intern Med. 2021;60(21):3459–3462. doi:10.2169/internalmedicine.5922-20
- 55. Percik R, Nethanel A, Liel Y. Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment. Immunotherapy. 2021;13(8):653–659. doi:10.2217/imt-2020-0332
- 56. Del Bello A, Zakaroff AG, Meyer N, Delas A, Faguer S, Kamar N, Belliere J. Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. American Journal of Transplantation. 2021;21(7):2616–2618. doi:10.1111/ajt.16589
- 57. Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9(7):e002855. doi:10.1136/jitc-2021-002855

- 58. Olivares-Hernández A, Figuero-Pérez L, Amores Martín MA, Bellido Hernández L, Mezquita L, Vidal Tocino MDR, López Cadenas F, Gómez-Caminero López F, Escala-Cornejo RA, Cruz Hernández JJ. Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors. Case Rep Oncol Med. 2021;2021:6631859. doi:10.1155/2021/6631859
- 59. Kurozumi A, Takahashi H, Watanabe T, Iwasaki Y. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors. Thorac Cancer. 2021;12(10):1625–1628. doi:10.1111/1759-7714.13954
- 60. Masood A, Wahab A, Clifford T, Weaver EJ, Ehsan H, El Ayass W. Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report. Clinical Case Reports. 2021;9(12):e05184. doi:10.1002/ccr3.5184
- 61. Pacholczak-Madej R, Grela-Wojewoda A, Lompart J, Żuchowska-Vogelgesang B, Ziobro M. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy. Prague Med Rep. 2022;123(1):35–42. doi:10.14712/23362936.2022.4
- 62. Tiu C, Shinde R, Pal A, Biondo A, Lee A, Tunariu N, Jhanji S, Grover V, Tatham K, Gruber P, et al. A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. J Immunother Precis Oncol. 2021;4(4):189–195. doi:10.36401/JIPO-21-9
- 63. Zhang M, Cheng Y, Hu Y, Nie L. Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report. Thorac Cancer. 2022;13(9):1419–1422. doi:10.1111/1759-7714.14390
- 64. Chen X, Mo S, Yi B. The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories. BMC Public Health. 2022;22(1):987. doi:10.1186/s12889-022-13281-y
- 65. Sex differences in immune responses | Nature Reviews Immunology. [accessed June 28, 2022]. https://www.nature.com/articles/nri.2016.90
- 66. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel S-E, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509-523.e6. doi:10.1016/j.ccell.2022.04.004
- 67. Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–332. doi:10.1136/gutjnl-2016-311585
- 68. Liu H, Shen J, Lu K. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model. Biochem Biophys Res Commun. 2017;486(2):239–244. doi:10.1016/j.bbrc.2017.02.128
- 69. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell

- Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
- 70. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi:10.1126/scitranslmed.3008226
- 71. Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183(3):364–374. doi:10.1111/bjh.15644
- 72. Li M, Xue S-L, Tang X, Xu J, Chen S, Han Y, Qiu H, Miao M, Xu N, Tan J, et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep. 2022;12(1):378. doi:10.1038/s41598-021-04296-3
- 73. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8
- 74. Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134. doi:10.1016/j.ctrv.2020.102134
- 75. Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? Cancers (Basel). 2021;13(5):989. doi:10.3390/cancers13050989
- 76. Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat M-C, Puyade M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer. 2020;8(2):e001622. doi:10.1136/jitc-2020-001622
- 77. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane A-F, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020;6(6):865–871. doi:10.1001/jamaoncol.2020.0726
- 78. Xu S, Shukuya T, Tamura J, Shimamura S, Kurokawa K, Miura K, Miyawaki T, Hayakawa D, Asao T, Yamamoto K, et al. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep. 2022;3(4):100309. doi:10.1016/j.jtocrr.2022.100309